Clinical Pharmacology & Toxicology (Liechti)

Atila, C. et al. (2024) ‘Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials’, JAMA network open, 7(11). Available at: https://doi.org/10.1001/jamanetworkopen.2024.45278.

Holze, F. et al. (2024) ‘Ketanserin exhibits dose- and concentration-proportional serotonin 2A receptor occupancy in healthy individuals: Relevance for psychedelic research’, European Neuropsychopharmacology, 88, pp. 43–48. Available at: https://doi.org/10.1016/j.euroneuro.2024.07.003.

Klaiber, A. et al. (2024) ‘Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects’, Translational Psychiatry, 14(1). Available at: https://doi.org/10.1038/s41398-024-03116-2.

Calder, A.E. et al. (2024) ‘Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response’, Journal of Psychopharmacology [Preprint]. Available at: https://doi.org/10.1177/02698811241278873.

Avram, M. et al. (2024) ‘Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine’, Molecular Psychiatry [Preprint]. Available at: https://doi.org/10.1038/s41380-024-02734-y.

Straumann, I. et al. (2024) ‘Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants’, Neuropsychopharmacology [Preprint]. Available at: https://doi.org/10.1038/s41386-024-01972-6.

Arias, H.R. et al. (2024) ‘Non-hallucinogenic compounds derived from iboga alkaloids alleviate neuropathic and visceral pain in mice through a mechanism involving 5-HT2A receptor activation’, Biomedicine and Pharmacotherapy, 177. Available at: https://doi.org/10.1016/j.biopha.2024.116867.

Stocker, K. and Liechti, M.E. (2024) ‘Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: It is time to reconcile “the great entactogen—empathogen debate”’, Journal of Psychopharmacology, 38(8), pp. 685–689. Available at: https://doi.org/10.1177/02698811241265352.

Holze, F. et al. (2024) ‘LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up’, The British Journal of Psychiatry, pp. 1–9. Available at: https://doi.org/10.1192/bjp.2024.99.

Hutten, N.R.P.W. et al. (2024) ‘Inter-individual variability in neural response to low doses of LSD’, Translational Psychiatry, 14(1). Available at: https://doi.org/10.1038/s41398-024-03013-8.

Arias, Hugo R. et al. (2024) ‘The novel non-hallucinogenic compound DM506 (3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole) induces sedative- and anxiolytic-like activity in mice by a mechanism involving 5-HT 2A receptor activation’, European Journal of Pharmacology, 966. Available at: https://doi.org/10.1016/j.ejphar.2024.176329.

Atila, Cihan et al. (2024) ‘Psychopathological characteristics in patients with arginine vasopressin deficiency (central diabetes insipidus) and primary polydipsia compared to healthy controls’, European Journal of Endocrinology, 190, pp. 354–362. Available at: https://doi.org/10.1093/ejendo/lvae040.

Atila, C. et al. (2024) ‘Oxytocin, Not Vasopressin, Mediates High Incidence of MDMA-Induced Hyponatremia - A Complication Preventable by Fluid Restriction’. Elsevier BV. Available at: https://doi.org/10.2139/ssrn.4819307.

Avram, Mihai et al. (2024) ‘Effective Connectivity of Thalamocortical Interactions Following d-Amphetamine, LSD, and MDMA Administration’, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 9, pp. 522–532. Available at: https://doi.org/10.1016/j.bpsc.2023.07.010.

Holze, Friederike et al. (2024) ‘Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants’, British Journal of Clinical Pharmacology, 90, pp. 200–208. Available at: https://doi.org/10.1111/bcp.15887.

Holze, F., Liechti, M.E. and Müller, F. (2024) ‘Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms’, in Current Topics in Behavioral Neurosciences. Berlin, Heidelberg: Springer Berlin Heidelberg (Current Topics in Behavioral Neurosciences). Available at: https://doi.org/10.1007/7854_2024_510.

Holze, Friederike et al. (2024) ‘Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile’, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 9, pp. 472–489. Available at: https://doi.org/10.1016/j.bpsc.2024.01.007.

E-Wen McCulloch, D. et al. (2024) ‘Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects’, Neuroscience Applied, 3, p. 103938. Available at: https://doi.org/10.1016/j.nsa.2024.103938.

Liechti, Matthias E. (2024) ‘Psychedelics as medication?’, Revue Medicale Suisse, 20, pp. 118–119. Available at: https://doi.org/10.53738/revmed.2024.20.858.118.

Luethi, Dino et al. (2024) ‘Derivatization-free determination of chiral plasma pharmacokinetics of MDMA and its enantiomers’, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1238. Available at: https://doi.org/10.1016/j.jchromb.2024.124123.

Stocker, Kurt et al. (2024) ‘The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies’, Journal of Psychopharmacology, 38, pp. 80–100. Available at: https://doi.org/10.1177/02698811231199112.

Straumann, I. et al. (2024) ‘Safety pharmacology of acute psilocybin administration in healthy participants’, Neuroscience Applied, 3, p. 104060. Available at: https://doi.org/10.1016/j.nsa.2024.104060.

Thomann, Jan et al. (2024) ‘In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin’, Frontiers in Pharmacology, 15. Available at: https://doi.org/10.3389/fphar.2024.1391689.

Thomann, Jan et al. (2024) ‘Development and validation of an LC-MS/MS method for quantifying diamorphine and its major metabolites 6-monoacetylmorphine, morphine, morphine-3-glucuronide, and morphine-6-glucuronide in human plasma’, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1237. Available at: https://doi.org/10.1016/j.jchromb.2024.124104.

Waters, M.L. et al. (2024) ‘Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020’, Clinical Toxicology, 62(6), pp. 378–384. Available at: https://doi.org/10.1080/15563650.2024.2346125.

Ley, Laura et al. (2023) ‘Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants’, Neuropsychopharmacology, 48(11), pp. 1659–1667. Available at: https://doi.org/10.1038/s41386-023-01607-2.

Anderson, C.E. et al. (2023) ‘Temporal development of unfavourable urodynamic parameters during the first year after spinal cord injury’, BJU International, 131(4), pp. 503–512. Available at: https://doi.org/10.1111/bju.15918.

Angerer, V. et al. (2023) ‘Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study’, Drug Testing and Analysis, null. Available at: https://doi.org/10.1002/dta.3622.

Atila, Cihan et al. (2023) ‘Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial’, The Lancet Diabetes and Endocrinology, 11, pp. 454–464. Available at: https://doi.org/10.1016/s2213-8587(23)00120-1.

Becker, Anna M. et al. (2023) ‘Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants’, International Journal of Neuropsychopharmacology, 26, pp. 97–106. Available at: https://doi.org/10.1093/ijnp/pyac075.

Bedford, Peter et al. (2023) ‘The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity’, Neuropsychopharmacology, 48, pp. 1175–1183. Available at: https://doi.org/10.1038/s41386-023-01574-8.

Halberstadt, Adam L. et al. (2023) ‘Use of the head-twitch response to investigate the structure–activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines’, Psychopharmacology, 240, pp. 115–126. Available at: https://doi.org/10.1007/s00213-022-06279-2.

Holze, Friederike et al. (2023) ‘Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants’, Clinical Pharmacology and Therapeutics, 113, pp. 822–831. Available at: https://doi.org/10.1002/cpt.2821.

Holze, Friederike et al. (2023) ‘Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study’, Biological Psychiatry, 93, pp. 215–223. Available at: https://doi.org/10.1016/j.biopsych.2022.08.025.

Ley, Laura et al. (2023) ‘Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants’, Neuropsychopharmacology, 48, pp. 1659–1667. Available at: https://doi.org/10.1038/s41386-023-01607-2.

Miró, Òscar et al. (2023) ‘Severity of emergency department presentations due to acute drug toxicity in Europe: A longitudinal analysis over a 6-year period (2014-2019) stratified by sex’, European Journal of Emergency Medicine, 30, pp. 21–31. Available at: https://doi.org/10.1097/mej.0000000000000978.

Noseda, Roberta et al. (2023) ‘Determinants of Admission to Critical Care Following Acute Recreational Drug Toxicity: A Euro-DEN Plus Study’, Journal of Clinical Medicine, 12. Available at: https://doi.org/10.3390/jcm12185970.

Reissmann, Steffen et al. (2023) ‘Case report: Maintaining altered states of consciousness over repeated ketamine infusions may be key to facilitate long-lasting antidepressant effects: some initial lessons from a personalized-dosing single-case study’, Frontiers in Psychiatry, 14. Available at: https://doi.org/10.3389/fpsyt.2023.1197697.

Straumann, Isabelle et al. (2023) ‘Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants’, Neuropsychopharmacology, 48, pp. 1840–1848. Available at: https://doi.org/10.1038/s41386-023-01609-0.

Vallersnes, O.M. et al. (2023) ‘Self-discharge during treatment for acute recreational drug toxicity: an observational study from emergency departments in seven European countries’, International Journal of Emergency Medicine, 16. Available at: https://doi.org/10.1186/s12245-023-00566-1.

Vogt, Severin B. et al. (2023) ‘Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants’, Translational Psychiatry, 13. Available at: https://doi.org/10.1038/s41398-023-02477-4.

Thomann J et al. (2022) ‘Development and validation of an LC-MS/MS method for the quantification of mescaline and major metabolites in human plasma.’, Journal of pharmaceutical and biomedical analysis, 220, p. 114980. Available at: https://doi.org/10.1016/j.jpba.2022.114980.

Stocker K. et al. (2022) ‘Buddhist-like opposite diminishing and non-judging during ketamine infusion are associated with antidepressant response: an open-label personalized-dosing study’, Frontiers in Pharmacology, 13. Available at: https://doi.org/10.3389/fphar.2022.916641.

Kolaczynska K.E. et al. (2022) ‘Pharmacological characterization of 3,4-methylenedioxamphetamine (MDA) analogs and two amphetamine-based compounds: N,α-DEPEA and DPIA’, European Neuropsychopharmacology, 59, pp. 9–22. Available at: https://doi.org/10.1016/j.euroneuro.2022.03.006.

Luethi D. and Liechti M.E. (2022) ‘Correction to: Designer drugs: mechanism of action and adverse effects (Archives of Toxicology, (2020), 94, 4, (1085-1133), 10.1007/s00204-020-02693-7)’, Archives of Toxicology, 96(5), p. 1489. Available at: https://doi.org/10.1007/s00204-022-03244-y.

Ilic M. et al. (2022) ‘Corrigendum: Cell-Based Radiotracer Binding and Uptake Inhibition Assays: A Comparison of In Vitro Methods to Assess the Potency of Drugs That Target Monoamine Transporters(Front. Pharmacol., (2020), 11, (673), 10.3389/fphar.2020.00673)’, Frontiers in Pharmacology, 13. Available at: https://doi.org/10.3389/fphar.2022.878641.

Avram, Mihai et al. (2022) ‘Characterizing Thalamocortical (Dys)connectivity Following D-Amphetamine, LSD, and MDMA Administration’, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 7, pp. 885–894. Available at: https://doi.org/10.1016/j.bpsc.2022.04.003.

Becker, Anna M. et al. (2022) ‘Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects’, Clinical Pharmacology & Therapeutics, 111(4), pp. 886–895. Available at: https://doi.org/10.1002/cpt.2487.

Holze, Friederike et al. (2022) ‘Safety pharmacology of acute LSD administration in healthy subjects’, Psychopharmacology, 239(6), pp. 1893–1905. Available at: https://doi.org/10.1007/s00213-021-05978-6.

Holze, Friederike et al. (2022) ‘Correction to: Safety pharmacology of acute LSD administration in healthy subjects’, Psychopharmacology, 239(2), p. 661. Available at: https://doi.org/10.1007/s00213-021-05988-4.

Holze, Friederike et al. (2022) ‘Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects’, Neuropsychopharmacology, 47(6), pp. 1180–1187. Available at: https://doi.org/10.1038/s41386-022-01297-2.

Kolaczynska, Karolina E. et al. (2022) ‘Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines’, Frontiers in Pharmacology, 12, p. 794254. Available at: https://doi.org/10.3389/fphar.2021.794254.

Liechti, Matthias E. and Holze, Friederike (2022) ‘Dosing Psychedelics and MDMA’. Springer Science and Business Media Deutschland GmbH, pp. 3–21. Available at: https://doi.org/10.1007/7854_2021_270.

Müller, Felix et al. (2022) ‘Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants’, Psychopharmacology, 239(6), pp. 1933–1943. Available at: https://doi.org/10.1007/s00213-022-06066-z.

Preveden N et al. (2022) ‘Metamizole as a Rare Cause of Drug-Induced Liver Injury’, European Journal of Case Reports in Internal Medicine, 9(5). Available at: https://doi.org/10.12890/2022_003349.

Schmid Y et al. (2022) ‘Differences in clinical features associated with cannabis intoxication in presentations to European emergency departments according to patient age and sex’, Clinical Toxicology, 60(8), pp. 912–919. Available at: https://doi.org/10.1080/15563650.2022.2060116.

Vizeli P et al. (2022) ‘Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects.’, Frontiers in pharmacology, 13, p. 906639. Available at: https://doi.org/10.3389/fphar.2022.906639.

Schmid Y et al. (2021) ‘Acute subjective effects in LSD- and MDMA-assisted psychotherapy.’, Journal of psychopharmacology (Oxford, England), 35(4), pp. 362–374. Available at: https://doi.org/10.1177/0269881120959604.

Kolaczynska KE, Liechti ME and Duthaler U (2021) ‘Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin’s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma.’, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1164, p. 122486. Available at: https://doi.org/10.1016/j.jchromb.2020.122486.

Noseda R et al. (2021) ‘MDMA-related presentations to the emergency departments of the European Drug Emergencies Network plus (Euro-DEN Plus) over the four-year period 2014-2017.’, Clinical toxicology (Philadelphia, Pa.), 59(2), pp. 131–137. Available at: https://doi.org/10.1080/15563650.2020.1784914.

Holze, Friederike et al. (2021) ‘Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin’, Frontiers in Pharmacology, 12, p. 711255. Available at: https://doi.org/10.3389/fphar.2021.711255.

Holze, Friederike et al. (2021) ‘Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants’, Clinical Pharmacology and Therapeutics, 109, pp. 658–666. Available at: https://doi.org/10.1002/cpt.2057.

Holze, Friederike et al. (2021) ‘Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects’, Neuropsychopharmacology, 46, pp. 537–544. Available at: https://doi.org/10.1038/s41386-020-00883-6.

Hutten, Nadia R. P. W. et al. (2021) ‘Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers’, ACS pharmacology & translational science, 4(2), pp. 461–466. Available at: https://doi.org/10.1021/acsptsci.0c00099.

Kolaczynska, Karolina E. et al. (2021) ‘The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative’, International journal of molecular sciences, 22(15), p. 8277. Available at: https://doi.org/10.3390/ijms22158277.

Liechti M.E. et al. (2021) ‘Pharmacological profiling of novel psychoactive substances’. Elsevier, pp. 109–130. Available at: https://doi.org/10.1016/b978-0-12-818788-3.00003-6.

Luethi D. and Liechti M.E. (2021) ‘Drugs of Abuse Affecting 5-HT2B Receptors’. Humana Press Inc., pp. 277–289. Available at: https://doi.org/10.1007/978-3-030-55920-5_16.

Miro O. et al. (2021) ‘Variation of drugs involved in acute drug toxicity presentations based on age and sex: an epidemiological approach based on European emergency departments’, Clinical Toxicology, 59(10), pp. 896–904. Available at: https://doi.org/10.1080/15563650.2021.1884693.

Müller, Felix et al. (2021) ‘MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens’, Neuropsychopharmacology, 46, pp. 545–553. Available at: https://doi.org/10.1038/s41386-020-00906-2.

Ramaekers, Johannes G. et al. (2021) ‘A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers’, Journal of Psychopharmacology, 35(4), pp. 398–405. Available at: https://doi.org/10.1177/0269881120940937.

Rudin, Deborah, Liechti, Matthias E. and Luethi, Dino (2021) ‘Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics’, Experimental Neurology, 343, p. 113778. Available at: https://doi.org/10.1016/j.expneurol.2021.113778.

Studerus, Erich et al. (2021) ‘Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies’, Journal of Psychopharmacology, 35(5), pp. 556–565. Available at: https://doi.org/10.1177/0269881121998322.

Vizeli, Patrick et al. (2021) ‘Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis’, Scientific reports, 11(1), p. 10851. Available at: https://doi.org/10.1038/s41598-021-90343-y.

Mégarbane B et al. (2020) ‘The neurobehavioral effects of the designer drug naphyrone - an experimental investigation with pharmacokinetics and concentration/effect relationship in mice.’, Psychopharmacology, 237(7), pp. 1943–1957. Available at: https://doi.org/10.1007/s00213-020-05510-2.

Grafinger, Katharina Elisabeth, Liechti, Matthias E. and Liakoni, Evangelia (2020) ‘Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication’, British Journal of Clinical Pharmacology, 86(3), pp. 429–436. Available at: https://doi.org/10.1111/bcp.14115.

Holze, Friederike et al. (2020) ‘Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects’, Neuropsychopharmacology, 45(3), pp. 462–471. Available at: https://doi.org/10.1038/s41386-019-0569-3.

Hutten, Nadia R.P.W. et al. (2020) ‘Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study’, European Neuropsychopharmacology, 41, pp. 81–91. Available at: https://doi.org/10.1016/j.euroneuro.2020.10.002.

Ilic M et al. (2020) ‘Cell-Based Radiotracer Binding and Uptake Inhibition Assays: A Comparison of In Vitro Methods to Assess the Potency of Drugs That Target Monoamine Transporters.’, Frontiers in pharmacology, 11, p. 673. Available at: https://doi.org/10.3389/fphar.2020.00673.

Luethi, Dino and Liechti, Matthias E. (2020) ‘Designer drugs: mechanism of action and adverse effects’, Archives of Toxicology, 94(4), pp. 1085–1133. Available at: https://doi.org/10.1007/s00204-020-02693-7.

Müller, Felix et al. (2020) ‘Treatment of a Complex Personality Disorder Using Repeated Doses of LSD—A Case Report on Significant Improvements in the Absence of Acute Drug Effects’, Frontiers in Psychiatry, 11. Available at: https://doi.org/10.3389/fpsyt.2020.573953.

Schmid, Yasmin et al. (2020) ‘Emergency department presentations related to acute toxicity following recreational use of cannabis products in Switzerland’, Drug and Alcohol Dependence, 206, p. 107726. Available at: https://doi.org/10.1016/j.drugalcdep.2019.107726.

Steuer, Andrea E. et al. (2020) ‘Comparative untargeted metabolomics analysis of the psychostimulants 3,4-methylenedioxy-methamphetamine (MDMA), amphetamine, and the novel psychoactive substance mephedrone after controlled drug administration to humans’, Metabolites, 10, pp. 1–20. Available at: https://doi.org/10.3390/metabo10080306.

Zhou, Xun et al. (2020) ‘Hyperthermia Increases Neurotoxicity Associated with Novel Methcathinones’, Cells, 9(4), p. 965. Available at: https://doi.org/10.3390/cells9040965.

Zhou, Xun et al. (2020) ‘Para; -Halogenation of Amphetamine and Methcathinone Increases the Mitochondrial Toxicity in Undifferentiated and Differentiated SH-SY5Y Cells’, International journal of molecular sciences, 21(8), p. 2841. Available at: https://doi.org/10.3390/ijms21082841.

Bühler T, Schmid Y and Liechti ME (2019) ‘[Knockout Drugs: Diagnostics in the Emergency Unit and Clinical Practice].’, Praxis, 108(13), pp. 869–876. Available at: https://doi.org/10.1024/1661-8157/a003306.

Luethi D et al. (2019) ‘Monoamine receptor interaction profiles of 4-aryl-substituted 2,5-dimethoxyphenethylamines (2C-BI derivatives).’, European journal of pharmacology, 855, pp. 103–111. Available at: https://doi.org/10.1016/j.ejphar.2019.05.014.

Luethi D et al. (2019) ‘Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use.’, Biochemical pharmacology, 164, pp. 129–138. Available at: https://doi.org/10.1016/j.bcp.2019.04.013.

Rickli A et al. (2019) ‘Pharmacological characterization of the aminorex analogs 4-MAR, 4,4′-DMAR, and 3,4-DMAR.’, Neurotoxicology, 72, pp. 95–100. Available at: https://doi.org/10.1016/j.neuro.2019.02.011.

Holze, Friederike et al. (2019) ‘Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects’, British Journal of Clinical Pharmacology, 85, pp. 1474–1483. Available at: https://doi.org/10.1111/bcp.13918.

Kolaczynska, Karolina E. et al. (2019) ‘Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines’, Frontiers in Pharmacology, 10, p. 1423. Available at: https://doi.org/10.3389/fphar.2019.01423.

Leuppi-Taegtmeyer, Anne et al. (2019) ‘Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions’, Nephrology, Dialysis, Transplantation, 34(4), pp. 692–702. Available at: https://doi.org/10.1093/ndt/gfy285.

Luethi, Dino et al. (2019) ‘Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems’, Journal of Psychopharmacology, 33(7), pp. 831–841. Available at: https://doi.org/10.1177/0269881119844185.

Luethi D et al. (2019) ‘Para-Halogenation Affects Monoamine Transporter Inhibition Properties and Hepatocellular Toxicity of Amphetamines and Methcathinones.’, Frontiers in pharmacology, 10, p. 438. Available at: https://doi.org/10.3389/fphar.2019.00438.

Mayer, Felix P. et al. (2019) ‘Stereochemistry of phase-1 metabolites of mephedrone determines their effectiveness as releasers at the serotonin transporter’, Neuropharmacology, 148, pp. 199–209. Available at: https://doi.org/10.1016/j.neuropharm.2018.12.032.

Müller, Felix et al. (2019) ‘Neuroimaging of chronic MDMA (‘ecstasy’) effects: A meta-analysis’, Neuroscience and biobehavioral reviews, 96, pp. 10–20. Available at: https://doi.org/10.1016/j.neubiorev.2018.11.004.

Rickli, Anna, Hoener, Marius C. and Liechti, Matthias E. (2019) ‘Pharmacological profiles of compounds in preworkout supplements (‘boosters’)’, European Journal of Pharmacology, 859, p. 172515. Available at: https://doi.org/10.1016/j.ejphar.2019.172515.

Scholz, Irene et al. (2019) ‘Emergency department presentations related to abuse of prescription and over-the-counter drugs in Switzerland: time trends, sex and age distribution’, Swiss Medical Weekly, 149, p. w20056. Available at: https://doi.org/10.4414/smw.2019.20056.

Strajhar, Petra et al. (2019) ‘Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: A randomized, double-blind, placebo-controlled study’, Journal of Steroid Biochemistry and Molecular Biology, 186, pp. 212–225. Available at: https://doi.org/10.1016/j.jsbmb.2018.10.016.

Vizeli, Patrick and Liechti, Matthias E. (2019) ‘No Influence of Dopamine System Gene Variations on Acute Effects of MDMA’, Frontiers in Psychiatry, 10, p. 755. Available at: https://doi.org/10.3389/fpsyt.2019.00755.

Vizeli, Patrick, Meyer Zu Schwabedissen, Henriette E. and Liechti, Matthias E. (2019) ‘Role of serotonin transporter and receptor gene variations in the acute effects of MDMA in healthy subjects’, ACS chemical neuroscience, 10(7), pp. 3120–3131. Available at: https://doi.org/10.1021/acschemneuro.8b00590.